Business
NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the 'Treat Early' Strategy
At the 62nd European Renal Association Congress (ERA 2025), nine new studies on NEFECON® were presented, two of which demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy of "Treat the Cause, Treat Early, Treat All".
About this update from Everest Medicines Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy: "Treat the Cause, Treat Early, Treat All":","length":253,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":253,"olType":false},{"type":"text","content":"— A subanalysis of the NefIgArd study demonstrates that early treatment can more effectively slow disease progression and reduce irreversible nephron loss.","length":155,"tagName":"p","attribs":{}},{"type":"text","content":"— A prospective study indicates that early treatment with NEFECON® in patients diagnosed within 6 months may better control inflammatory responses and delay disease progression.","length":177,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI, June 6, 2025 /PRNewswire/ -- At the 62nd European Renal Association Congress (ERA 2025), nine new studies on NEFECON® were presented, two of which demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease management strategy of "Treat the Cause, Treat Early, Treat All".","length":379,"tagName":"p"},{"type":"text","content":"The new results presented at ERA 2025 demonstrate early treatment with NEFECON® can help protect renal function and slow disease progression, leading to improved disease management and an improved quality of life for patients.","length":231,"tagName":"p"},{"type":"text","content":""The new results have validated the significant role of NEFECON® in the early intervention of IgAN, and have fully demonstrated its key value in the strategy of 'Treat the Cause, Treat Early, Treat All'." said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, "These findings further underscore its outstanding clinical advantages as a first-line cornerstone therapy for IgAN. The 'Treat Early' strategy offers more proactive treatment for IgAN patients, helping to control disease progression and better protect renal function. NEFECON® is the first and only fully approved etiological treatment for IgAN in China, the U.S., and Europe, providing patients with new hope and treatment options.","length":751,"tag...